Intact CEO Bruce Shook Excited by New Round, Clinical Progress, and the Potential for Spin-off, Vesper
Intact Vascular recently secured an additional $20m to push the Tack Endovascular System to PMA approval. CEO Bruce Shook discusses the round, the potential for Tack, and shares that he's actually the CEO of TWO Medtech start-ups.
Intact CEO Bruce Shook Excited by New Round, Clinical Progress, and the Potential for Spin-off, Vesper
Intact Vascular recently secured an additional $20m to push the Tack Endovascular System to PMA approval. CEO Bruce Shook discusses the round, the potential for Tack, and shares that he's actually the CEO of TWO Medtech start-ups.